NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TEVA shares have increased by 28.9% and is now trading at $11.61. View which stocks have been most impacted by Coronavirus.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its quarterly earnings data on Thursday, May, 7th. The company reported $0.76 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.59 by $0.17. The firm earned $4.36 billion during the quarter, compared to analysts' expectations of $4.15 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.10% and a negative net margin of 4.73%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $0.60 EPS. View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.44. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.

22 analysts have issued 12 month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $11.50 in the next year. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Teva Pharmaceutical Industries.

Headlines about TEVA stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a news impact score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS) and Catalent (CTLT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Cisco Systems (CSCO) and Walt Disney (DIS).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs. View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Sol J Barer, and Sven Dethlefs. View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $11.61.

Teva Pharmaceutical Industries has a market capitalization of $12.68 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]